Cardioprotective effects of a novel hydrogen sulfide agent-controlled release formulation of S-propargyl-cysteine on heart failure rats and molecular mechanisms.

Article English OPEN
Huang, Chengrong; Kan, Juntao; Liu, Xu; Ma, Fenfen; Tran, Ba Hieu; Zou, Yunzeng; Wang, Shujun; Zhu, Yi Zhun;
  • Publisher: Public Library of Science (PLoS)
  • Journal: PLoS ONE,volume 8,issue 7 (issn: 1932-6203, eissn: 1932-6203)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.1371/journal.pone.0069205, pmc: PMC3706411
  • Subject: Coronary Artery Disease | Heart Failure | Animal Models | Research Article | Biology | Molecular Cell Biology | Rat | Cell Death | Myocardial Infarction | Medicine | Drug Research and Development | Cardiovascular | Cardiovascular Pharmacology | Q | R | Drug Discovery | Model Organisms | Drugs and Devices | Biochemistry | Science | Small Molecules

OBJECTIVE: Heart failure (HF) is one of the most serious diseases worldwide. S-propargyl-cysteine (SPRC), a novel modulator of endogenous hydrogen sulfide, is proved to be able to protect against acute myocardial ischemia. In order to produce more stable and sustainable... View more
Share - Bookmark